Related Experiment Videos
Deferred treatment for prostate cancer
British Journal of Urology
|September 1, 1988
Summary
Deferred treatment for asymptomatic prostate cancer patients resulted in a 5-year survival rate of 30%. Factors like poor tumor grade and metastatic disease indicated a worse prognosis for these men.
Area of Science:
- Oncology
- Urology
- Clinical Medicine
Background:
- Prostate cancer management often involves immediate treatment.
- Deferred treatment, or watchful waiting, is an option for select asymptomatic patients.
- Understanding outcomes for deferred treatment is crucial for clinical decision-making.
Purpose of the Study:
- To retrospectively analyze the clinical outcomes of prostate cancer patients managed with a deferred treatment policy.
- To identify prognostic factors associated with survival in this cohort.
Main Methods:
- Retrospective analysis of 278 prostate cancer patients.
- Patients were asymptomatic post-TURP or biopsy and managed expectantly.
- Treatment (hormone therapy) was initiated only upon symptomatic progression.
Main Results:
- Overall 5-year survival rate was 30%.
- 17% died from prostate cancer, while 18% died from other causes.
- 11% remained alive and untreated after 5 years.
- Poor tumor grade, anemia, metastatic disease, and elevated creatinine predicted a poor prognosis.
Conclusions:
- Deferred treatment for asymptomatic prostate cancer can lead to long-term survival in some patients.
- However, a significant proportion may die from the disease.
- Prognostic factors identified can help stratify risk within this management strategy.